Drug Trial Radar · NCT06762600
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Jan 16, 2025
Primary completion
Mar 12, 2026
Study completion Mar 12, 2026
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.
Conditions
- Overweight or Obesity
Interventions
HRS-4729 injectionDrug
HRS-4729 injection
HRS-4729 injection placeboDrug
HRS-4729 injection placebo
HRS9531 injectionDrug
HRS9531 injection
HRS9531 injection placeboDrug
HRS9531 injection placebo
AcetaminophenDrug
Acetaminophen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: Screening period up to day 43.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jinan Central Hospital
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.